Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) - Net Assets
Based on the latest financial reports, Profarma Distribuidora de Produtos Farmacêuticos S.A (PFRM3) has net assets worth R$1.67 Billion BRL (≈ $328.16 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (R$5.64 Billion ≈ $1.11 Billion USD) and total liabilities (R$3.96 Billion ≈ $777.76 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check PFRM3 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | R$1.67 Billion |
| % of Total Assets | 29.67% |
| Annual Growth Rate | 17.64% |
| 5-Year Change | 10.49% |
| 10-Year Change | 137.42% |
| Growth Volatility | 85.22 |
Profarma Distribuidora de Produtos Farmacêuticos S.A - Net Assets Trend (2003–2024)
This chart illustrates how Profarma Distribuidora de Produtos Farmacêuticos S.A's net assets have evolved over time, based on quarterly financial data. Also explore PFRM3 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Profarma Distribuidora de Produtos Farmacêuticos S.A (2003–2024)
The table below shows the annual net assets of Profarma Distribuidora de Produtos Farmacêuticos S.A from 2003 to 2024. For live valuation and market cap data, see PFRM3 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | R$1.59 Billion ≈ $311.17 Million |
+3.04% |
| 2023-12-31 | R$1.54 Billion ≈ $301.98 Million |
+1.88% |
| 2022-12-31 | R$1.51 Billion ≈ $296.41 Million |
+2.35% |
| 2021-12-31 | R$1.48 Billion ≈ $289.60 Million |
+2.83% |
| 2020-12-31 | R$1.44 Billion ≈ $281.62 Million |
+42.86% |
| 2019-12-31 | R$1.00 Billion ≈ $197.13 Million |
-1.62% |
| 2018-12-31 | R$1.02 Billion ≈ $200.38 Million |
+36.90% |
| 2017-12-31 | R$745.93 Million ≈ $146.37 Million |
-1.72% |
| 2016-12-31 | R$758.96 Million ≈ $148.92 Million |
+13.63% |
| 2015-12-31 | R$667.95 Million ≈ $131.06 Million |
-3.03% |
| 2014-12-31 | R$688.85 Million ≈ $135.17 Million |
+20.52% |
| 2013-12-31 | R$571.56 Million ≈ $112.15 Million |
+0.11% |
| 2012-12-31 | R$570.93 Million ≈ $112.03 Million |
+5.44% |
| 2011-12-31 | R$541.47 Million ≈ $106.25 Million |
+4.35% |
| 2010-12-31 | R$518.89 Million ≈ $101.82 Million |
+6.91% |
| 2009-12-31 | R$485.37 Million ≈ $95.24 Million |
+3.83% |
| 2008-12-31 | R$467.44 Million ≈ $91.72 Million |
+5.42% |
| 2007-12-31 | R$443.42 Million ≈ $87.01 Million |
+9.63% |
| 2006-12-31 | R$404.47 Million ≈ $79.37 Million |
+405.93% |
| 2005-12-31 | R$79.95 Million ≈ $15.69 Million |
+18.11% |
| 2004-12-31 | R$67.69 Million ≈ $13.28 Million |
+29.45% |
| 2003-12-31 | R$52.29 Million ≈ $10.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Profarma Distribuidora de Produtos Farmacêuticos S.A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6170.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | R$686.89 Million | 52.71% |
| Common Stock | R$918.66 Million | 70.50% |
| Total Equity | R$1.30 Billion | 100.00% |
Profarma Distribuidora de Produtos Farmacêuticos S.A Competitors by Market Cap
The table below lists competitors of Profarma Distribuidora de Produtos Farmacêuticos S.A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mycenax Biotech
TWO:4726
|
$191.04 Million |
|
Lippo Cikarang Tbk
JK:LPCK
|
$191.05 Million |
|
Elme Communities
NYSE:ELME
|
$191.13 Million |
|
Sinmag Equipment
TWO:1580
|
$191.20 Million |
|
Gem Terminal Industry Co Ltd
TW:2460
|
$190.84 Million |
|
AMA Group Ltd
AU:AMA
|
$190.78 Million |
|
Hi-Clearance
TWO:1788
|
$190.76 Million |
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class A
IS:KRDMA
|
$190.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Profarma Distribuidora de Produtos Farmacêuticos S.A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,248,348,000 to 1,303,101,000, a change of 54,753,000 (4.4%).
- Net income of 114,579,000 contributed positively to equity growth.
- Dividend payments of 54,579,000 reduced retained earnings.
- Other comprehensive income decreased equity by 40,980,999.
- Other factors increased equity by 35,733,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | R$114.58 Million | +8.79% |
| Dividends Paid | R$54.58 Million | -4.19% |
| Other Comprehensive Income | R$-40.98 Million | -3.14% |
| Other Changes | R$35.73 Million | +2.74% |
| Total Change | R$- | 4.39% |
Book Value vs Market Value Analysis
This analysis compares Profarma Distribuidora de Produtos Farmacêuticos S.A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.75x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.88x to 0.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | R$2.75 | R$7.94 | x |
| 2005-12-31 | R$3.25 | R$7.94 | x |
| 2006-12-31 | R$10.20 | R$7.94 | x |
| 2007-12-31 | R$11.18 | R$7.94 | x |
| 2008-12-31 | R$11.95 | R$7.94 | x |
| 2009-12-31 | R$13.28 | R$7.94 | x |
| 2010-12-31 | R$13.83 | R$7.94 | x |
| 2011-12-31 | R$14.06 | R$7.94 | x |
| 2012-12-31 | R$15.62 | R$7.94 | x |
| 2013-12-31 | R$15.75 | R$7.94 | x |
| 2014-12-31 | R$15.64 | R$7.94 | x |
| 2015-12-31 | R$15.04 | R$7.94 | x |
| 2016-12-31 | R$12.74 | R$7.94 | x |
| 2017-12-31 | R$10.32 | R$7.94 | x |
| 2018-12-31 | R$8.72 | R$7.94 | x |
| 2019-12-31 | R$8.19 | R$7.94 | x |
| 2020-12-31 | R$8.53 | R$7.94 | x |
| 2021-12-31 | R$8.86 | R$7.94 | x |
| 2022-12-31 | R$9.71 | R$7.94 | x |
| 2023-12-31 | R$10.18 | R$7.94 | x |
| 2024-12-31 | R$10.63 | R$7.94 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Profarma Distribuidora de Produtos Farmacêuticos S.A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.79%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.13%
- • Asset Turnover: 1.81x
- • Equity Multiplier: 4.31x
- Recent ROE (8.79%) is above the historical average (5.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 20.95% | 1.12% | 3.65x | 5.13x | R$5.72 Million |
| 2004 | 28.17% | 1.51% | 3.75x | 4.97x | R$12.30 Million |
| 2005 | 20.37% | 1.07% | 3.53x | 5.39x | R$8.29 Million |
| 2006 | -0.88% | -0.21% | 2.23x | 1.92x | R$-44.00 Million |
| 2007 | 10.61% | 2.07% | 2.45x | 2.08x | R$2.69 Million |
| 2008 | 6.77% | 1.25% | 2.75x | 1.97x | R$-15.10 Million |
| 2009 | 10.95% | 2.06% | 2.55x | 2.08x | R$4.62 Million |
| 2010 | 6.63% | 1.31% | 2.45x | 2.06x | R$-17.51 Million |
| 2011 | 4.97% | 0.80% | 2.69x | 2.32x | R$-26.78 Million |
| 2012 | 7.23% | 1.26% | 2.26x | 2.55x | R$-15.53 Million |
| 2013 | 3.55% | 0.59% | 1.95x | 3.10x | R$-36.97 Million |
| 2014 | -7.57% | -1.51% | 1.89x | 2.65x | R$-121.00 Million |
| 2015 | -3.17% | -0.61% | 1.52x | 3.42x | R$-87.98 Million |
| 2016 | -6.45% | -1.20% | 1.51x | 3.57x | R$-124.86 Million |
| 2017 | -15.11% | -2.75% | 1.57x | 3.51x | R$-187.31 Million |
| 2018 | -0.95% | -0.23% | 1.48x | 2.83x | R$-111.86 Million |
| 2019 | 1.19% | 0.25% | 1.51x | 3.17x | R$-88.49 Million |
| 2020 | 5.00% | 0.95% | 1.46x | 3.59x | R$-52.30 Million |
| 2021 | 7.20% | 1.22% | 1.59x | 3.71x | R$-30.41 Million |
| 2022 | 6.79% | 1.03% | 1.79x | 3.66x | R$-38.23 Million |
| 2023 | 5.64% | 0.81% | 1.75x | 3.96x | R$-54.44 Million |
| 2024 | 8.79% | 1.13% | 1.81x | 4.31x | R$-15.73 Million |
Industry Comparison
This section compares Profarma Distribuidora de Produtos Farmacêuticos S.A's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.
About Profarma Distribuidora de Produtos Farmacêuticos S.A
Profarma Distribuidora de Produtos Farmacêuticos S.A., together with its subsidiaries, engages in the distribution of pharmaceutical products in Brazil. It provides pharmaceutical, personal hygiene, and beauty products. The company operates retail stores under the Drogasmil, Farmalife, Drogarias Tamoio and Drogaria Rosário brands. Profarma Distribuidora de Produtos Farmacêuticos S.A. was incorpor… Read more